399 related articles for article (PubMed ID: 35422075)
1. Predictors of impaired SARS-CoV-2 immunity in healthcare workers after vaccination with BNT162b2.
Bertram S; Blazquez-Navarro A; Seidel M; Hölzer B; Seibert FS; Doevelaar A; Rohn B; Zgoura P; Witte-Lack A; Skrzypczyk S; Scholten D; Kisters K; Babel N; Westhoff TH
Sci Rep; 2022 Apr; 12(1):6243. PubMed ID: 35422075
[TBL] [Abstract][Full Text] [Related]
2. Humoral immune response after different SARS-CoV-2 vaccination regimens.
Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
[TBL] [Abstract][Full Text] [Related]
3. Long-term quantitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV (PWH).
Tuan JJ; Zapata H; Barakat L; Andrews L; Behnegar A; Kim YW; Kayani J; Mutic S; Ryall L; Turcotte B; Critch-Gilfillan T; Zhao M; Salahuddin S; Gupta S; Sutton R; Friedland G; Emu B; Ogbuagu O
BMC Infect Dis; 2022 Sep; 22(1):744. PubMed ID: 36131232
[TBL] [Abstract][Full Text] [Related]
4. [Humoral immunity against SARS-CoV-2 in workers of social health care centers of Castilla y León after vaccination with the BNT162b2 mRNA vaccine from Pfizer/Biontech.].
Casas Fischer R
Rev Esp Salud Publica; 2021 Oct; 95():. PubMed ID: 34690347
[TBL] [Abstract][Full Text] [Related]
5. The association between adverse reactions and immune response against SARS-CoV-2 spike protein after vaccination with BNT162b2 among healthcare workers in a single healthcare system: a prospective observational cohort study.
Jubishi D; Okamoto K; Hamada K; Ishii T; Hashimoto H; Shinohara T; Yamashita M; Wakimoto Y; Otani A; Hisasue N; Ikeda M; Harada S; Okugawa S; Moriya K; Yanagimoto S
Hum Vaccin Immunother; 2022 Nov; 18(5):2048559. PubMed ID: 35333697
[TBL] [Abstract][Full Text] [Related]
6. Humoral response to the SARS-CoV-2 BNT162b2 mRNA vaccine: Real-world data from a large cohort of healthcare workers.
Oliveira-Silva J; Reis T; Lopes C; Batista-Silva R; Ribeiro R; Marques G; Pacheco V; Rodrigues T; Afonso A; Pinheiro V; Araújo L; Rodrigues F; Antunes I
Vaccine; 2022 Jan; 40(4):650-655. PubMed ID: 34952755
[TBL] [Abstract][Full Text] [Related]
7. Assessment of humoral and cellular immune responses to SARS CoV-2 vaccination (BNT162b2) in immunocompromised renal allograft recipients.
Zhang R; Shin BH; Gadsden TM; Petrosyan A; Vo A; Ammerman N; Sethi S; Huang E; Peng A; Najjar R; Atienza J; Kim I; Jordan SC
Transpl Infect Dis; 2022 Apr; 24(2):e13813. PubMed ID: 35202497
[TBL] [Abstract][Full Text] [Related]
8. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
Front Immunol; 2022; 13():827306. PubMed ID: 35173736
[TBL] [Abstract][Full Text] [Related]
9. Association between history of HBV vaccine response and anti-SARS-CoV-2 spike antibody response to the BioNTech/Pfizer's BNT162b2 mRNA SARS-CoV-2 vaccine among healthcare workers in Japan: A prospective observational study.
Iwamoto M; Ukimura A; Ogawa T; Kawanishi F; Osaka N; Kubota M; Mori T; Sawamura R; Nishihara M; Suzuki T; Uchiyama K
PLoS One; 2022; 17(5):e0268529. PubMed ID: 35576209
[TBL] [Abstract][Full Text] [Related]
10. Antibody Responses to the BNT162b2 mRNA Vaccine in Healthcare Workers in a General Hospital in Japan: A Comparison of Two Assays for Anti-spike Protein Immunoglobulin G.
Hibino M; Watanabe S; Kamada R; Tobe S; Maeda K; Horiuchi S; Kondo T
Intern Med; 2022 Mar; 61(6):811-819. PubMed ID: 34980798
[TBL] [Abstract][Full Text] [Related]
11. Assessment of humoral immune response to two mRNA SARS-CoV-2 vaccines (Moderna and Pfizer) in healthcare workers fully vaccinated with and without a history of previous infection.
Serrano L; Algarate S; Herrero-Cortina B; Bueno J; González-Barriga MT; Ducons M; Montero-Marco J; Acha B; Taboada A; Sanz-Burillo P; Yuste C; Benito R;
J Appl Microbiol; 2022 Sep; 133(3):1969-1974. PubMed ID: 35801660
[TBL] [Abstract][Full Text] [Related]
12. Humoral immune response following prime and boost BNT162b2 vaccination in people living with HIV on antiretroviral therapy.
Jedicke N; Stankov MV; Cossmann A; Dopfer-Jablonka A; Knuth C; Ahrenstorf G; Ramos GM; Behrens GMN
HIV Med; 2022 May; 23(5):558-563. PubMed ID: 34725907
[TBL] [Abstract][Full Text] [Related]
13. Impact of prior infection status on antibody response to the BNT162b2 mRNA COVID-19 vaccine in healthcare workers at a COVID-19 referral hospital in Milan, Italy.
Milazzo L; Pezzati L; Oreni L; Kullmann C; Lai A; Gabrieli A; Bestetti G; Beschi C; Conti F; Ottomano C; Gervasoni C; Meroni L; Galli M; Antinori S; Ridolfo AL
Hum Vaccin Immunother; 2021 Dec; 17(12):4747-4754. PubMed ID: 35086438
[TBL] [Abstract][Full Text] [Related]
14. Understanding "Hybrid Immunity": Comparison and Predictors of Humoral Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Vaccines.
Epsi NJ; Richard SA; Lindholm DA; Mende K; Ganesan A; Huprikar N; Lalani T; Fries AC; Maves RC; Colombo RE; Larson DT; Smith A; Chi SW; Maldonado CJ; Ewers EC; Jones MU; Berjohn CM; Libraty DH; Edwards MS; English C; Rozman JS; Mody RM; Colombo CJ; Samuels EC; Nwachukwu P; Tso MS; Scher AI; Byrne C; Rusiecki J; Simons MP; Tribble D; Broder CC; Agan BK; Burgess TH; Laing ED; Pollett SD;
Clin Infect Dis; 2023 Feb; 76(3):e439-e449. PubMed ID: 35608504
[TBL] [Abstract][Full Text] [Related]
15. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
16. Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer.
Debie Y; Van Audenaerde JRM; Vandamme T; Croes L; Teuwen LA; Verbruggen L; Vanhoutte G; Marcq E; Verheggen L; Le Blon D; Peeters B; Goossens ME; Pannus P; Ariën KK; Anguille S; Janssens A; Prenen H; Smits ELJ; Vulsteke C; Lion E; Peeters M; van Dam PA
Clin Cancer Res; 2023 Feb; 29(3):635-646. PubMed ID: 36341493
[TBL] [Abstract][Full Text] [Related]
17. Persistence of Immune Response in Health Care Workers After Two Doses BNT162b2 in a Longitudinal Observational Study.
Herzberg J; Fischer B; Lindenkamp C; Becher H; Becker AK; Honarpisheh H; Guraya SY; Strate T; Knabbe C
Front Immunol; 2022; 13():839922. PubMed ID: 35309303
[TBL] [Abstract][Full Text] [Related]
18. Humoral response to mRNA vaccines against SARS-CoV-2 in patients with humoral immunodeficiency disease.
Bitzenhofer M; Suter-Riniker F; Moor MB; Sidler D; Horn MP; Gschwend A; Staehelin C; Rauch A; Helbling A; Jörg L
PLoS One; 2022; 17(6):e0268780. PubMed ID: 35679232
[TBL] [Abstract][Full Text] [Related]
19. Detection of specific RBD
Del Pino Molina L; Bravo Gallego LY; Nozal P; Soto-Serrano Y; Martínez-Feito A; Reche-Yebra K; González-Torbay A; Cuesta-Martín de la Cámara R; Gianelli C; Cámara C; González-García J; González-Muñoz M; Rodríguez-Pena R; López Granados E
Front Immunol; 2023; 14():1136308. PubMed ID: 37215146
[TBL] [Abstract][Full Text] [Related]
20. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
